Greg Licholai

Dr. Greg Licholai is Chief Medical & Innovation Officer at ICON plc. Dr. Licholai is on faculty of Yale School of Management, Co-Director of the Center for Digital Health and teaches innovating healthcare at Harvard Business School. Previously, Dr. Licholai was President of rare disease at Moderna Therapeutics, President and Chief Medical Officer at Castle Creek Pharmaceuticals, and partner at McKinsey & Co. where he ran the healthcare data service line. Dr. Licholai was also a senior executive at Proteostasis, Amicus Therapeutics and Medtronic Neurological as well as venture investor for Domain Associates. Dr. Licholai was co-founder of Immunome Therapeutics.

Dr. Licholai has degrees from Harvard Business School, Yale School of Medicine, Columbia University and Boston College. Dr. Licholai trained at the Brigham and Women's, Children's, and Massachusetts General Hospitals. Dr. Licholai serves on multiple company and non-profit boards including advisor to the Clinical Trials Transformation Initiative (CTTI), a public private partnership co-founded by Duke University and the Food and Drug Administration (FDA). Dr. Licholai writes about innovation in healthcare for Forbes.